TY - JOUR T1 - Combination of Circulating Tumour DNA and <sup>18</sup>F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 270 LP - 281 DO - 10.21873/cgp.20319 VL - 19 IS - 2 AU - ONDREJ FIALA AU - JAN BAXA AU - MARTIN SVATON AU - LUCIE BENESOVA AU - RENATA PTACKOVA AU - TEREZA HALKOVA AU - MAREK MINARIK AU - PETR HOSEK AU - MARCELA BURESOVA AU - JINDRICH FINEK AU - JIRI FERDA AU - MILOS PESEK Y1 - 2022/03/01 UR - http://cgp.iiarjournals.org/content/19/2/270.abstract N2 - Background/Aim: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of advanced-stage NSCLC patients treated with chemotherapy. Patients and Methods: Eighty-four patients were enrolled in this study. 18F-fluorodeoxyglucose PET/CT and ctDNA assessments were performed at baseline and after two cycles of chemotherapy (follow-up). Results: There was a correlation of ctDNA with metabolic tumour volume (MTV), total lesion glycolysis (TLG), and iodine concentration (IC) at baseline (p=0.001, p=0.001, p=0.003) and at follow-up (p=0.006, p=0.002, p=0.001). The objective response was associated with follow-up ctDNA (p&lt;0.001) and the change of all PET/CT parameters. ROC analyses showed that the combination of follow-up ctDNA with changes in SUVmax is very promising for the estimation of objective response and progression-free survival. Conclusion: The combination of ctDNA assessment with PET/CT is a promising approach for the follow-up monitoring of therapy response and prognosis estimation of advanced-stage NSCLC patients. ER -